Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor widely used in the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.